Two different sizes of Valencia applicators in non-melanoma skin cancer treatment with iridium-192 high-dose-rate brachytherapy

被引:1
|
作者
Laliscia, Concetta [1 ]
Coccia, Natalina [1 ]
Fuentes, Taiusha [1 ]
Perrone, Franco [2 ]
Paiar, Fabiola [1 ]
机构
[1] Univ Pisa, Dept New Technol & Translat Res, Div Radiat Oncol, Via Roma 67, I-56127 Pisa, Italy
[2] Univ Pisa, Med Phys Dept, Pisa, Italy
关键词
non-melanoma skin cancer; brachytherapy; Valencia applicator; BASAL-CELL CARCINOMA; STANDARDIZED SURFACE APPLICATORS; RADIATION-THERAPY; HDR BRACHYTHERAPY; GUIDELINES; RECURRENCE;
D O I
10.5114/jcb.2021.112111
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this retrospective study was to analyze tumor control, toxicity, and aesthetic outcome of patients affected by non-melanoma skin cancer (NMSC) and treated with iridium-192 (192Ir) high-dose-rate (HDR) brachytherapy (BT) using Valencia applicators at the Division of Radiotherapy, University of Pisa. Material and methods: From June 2015 to December 2020, 95 NMSC patients, including 61.5% basal cell carcinoma and 38.5% squamous cell carcinoma patients, with median age of 83 years (range, 32-96 years) were treated. In total, 182 lesions with a diameter <= 25 mm (median, 12 mm) and a depth <= 4 mm, located in scalp (19.2%), face (20.9%), chest (8.8%), nose (16.5%), ear (15.4%), and extremities (19.2%) were analyzed. All lesions were treated with 192Ir-based HDR afterloader using Valencia applicators. 105 lesions (57.7%) were treated with applicator of 20 mm and 77 lesions (42.3%) with applicator of 30 mm in diameter, depending on the size of lesions. Prescribed dose was 40 Gy in 8 fractions (5 Gy/fraction) delivered 2-3 times a week. Biological effective dose (BED) was approximate to 60 Gy. Results: The median follow-up was 14 months (range, 3-59 months). The 2-year local control rate was 96%. According to common terminology criteria for adverse events (CTCAE v. 5.0), G1-G2 acute toxicities included dermatitis (22.0%) and pain (8.2%). The most common G1 late toxicities were hypopigmentation (27.5%) and fibrosis (8.2%), and G2 late toxicity included ulceration (0.5%). No G3 or higher acute or late toxicities were reported. Excellent cosmetic results were observed in 77.5% of the lesions, with one only (0.5%) reported as a poor cosmetic result (ulceration refractory to therapy). Conclusions: HDR-BT using Valencia applicators is a safe, effective, and well-tolerated treatment modality for NMSC, and can be considered a good alternative for treatment, especially in elderly patients who are often unfit for surgery.
引用
收藏
页码:615 / 619
页数:5
相关论文
共 50 条
  • [1] Treatment of non-melanoma superficial skin cancer with custom-made wax moulds using Iridium-192 high-dose-rate brachytherapy source
    Shah, Kamran Ali
    Ahmad, Habib
    Khattak, Muhammad Rauf
    Ahmad, Misbah
    Javed, Nabila
    Shah, Syed Jawad Ali
    Shaheen, Wajeeha
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2018, 17 (01) : 53 - 59
  • [2] High-dose-rate brachytherapy using Leipzig applicators for non-melanoma localized skin cancer
    Assis Pellizzon, Antonio Cassio
    Fogaroli, Ricardo
    Chen, Michael Jenwei
    Maia, Polyana
    Gondim, Guilherme
    Guedes, Douglas de Castro
    Ramos, Henderson
    Gobo Silva, Maria Leticia
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (05) : 435 - 440
  • [3] High-dose-rate brachytherapy in the treatment of non-melanoma skin cancer.
    Gonzalez Ruiz, M. A.
    Quiros Rivero, J.
    Cruz Munoz, M. C.
    Cabrera Rodriguez, J. J.
    Munoz Garcia, J. L.
    Rios Kavadoy, Y.
    Ropero Carmona, M. F.
    Corbacho Campos, A.
    Garcia Urra, F.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : E581 - E581
  • [4] A dosimetric comparison of Xoft Axxent Electronic Brachytherapy and iridium-192 high-dose-rate brachytherapy in the treatment of endometrial cancer
    Dickler, Adam
    Kirk, Michael C.
    Coon, Alan
    Bernard, Damian
    Zusag, Tom
    Rotmensch, Jacob
    Wazer, David E.
    BRACHYTHERAPY, 2008, 7 (04) : 351 - 354
  • [5] Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature
    Delishaj, Durim
    Rembielak, Agata
    Manfredi, Bruno
    Ursino, Stefano
    Pasqualetti, Francesco
    Laliscia, Concetta
    Orlandi, Francesca
    Morganti, Riccardo
    Fabrini, Maria Grazia
    Paiar, Fabiola
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (06) : 533 - 540
  • [6] Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a retrospective case series
    Delishaj, Durim
    Laliscia, Concetto
    Manfredi, Bruno
    Ursino, Stefano
    Pasqualetti, Francesco
    Lombardo, Ezio
    Perrone, Franco
    Morganti, Riccardo
    Paiar, Fabiola
    Fabrini, Maria Grazia
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2015, 7 (06) : 437 - 444
  • [7] Intraoperative and percutaneous iridium-192 high-dose-rate brachytherapy for previously irradiated lesions of the spine
    Folkert, Michael R.
    Bilsky, Mark H.
    Cohen, Gil'ad N.
    Zaider, Marco
    Lis, Eric
    Krol, George
    Laufer, Ilya
    Yamada, Yoshiya
    BRACHYTHERAPY, 2013, 12 (05) : 449 - 456
  • [8] High dose rate surface brachytherapy in non-melanoma skin cancer
    Pedrero, C. F.
    Alonso, S. Fernandez
    Gonzalez, S. Guardado
    Guillen, C. Arias
    Rodriguez, G. Pozo
    Saez, E. Capon
    Sanchez, A. Ferrando
    Ambrosi, R. D. Prime
    Gomez, J. F. Perez-Regadera
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1970 - S1971
  • [9] Tumor control and cosmetic outcome of weekly iridium-192 high-dose-rate brachytherapy for nonmelanoma skin cancers in the elderly
    Roberson, John
    Patel, Rushil
    Slutsky, Jordan B.
    Ryu, Samuel
    Xu, Zhigang
    Valentine, Edward
    BRACHYTHERAPY, 2021, 20 (04) : 818 - 827
  • [10] Dose rate effect: does it exist clinically in high-dose-rate intracavitary brachytherapy for cervical cancer using iridium-192 source?
    Wang, C
    Huang, E
    Sun, L
    Chen, H
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S237 - S237